PepGen IncNASDAQ:PEPG
- LAST PRICE18.5500
- TODAY'S CHANGE (%)0.5300 (2.9412%)
- Bid / Lots7.2600/ 2
- Ask / Lots24.0000/ 3
- Open / Previous Close18.3900 / 18.0200
- Day Range
- 52 Week Range
- Volume124,237
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PEPG |
|---|---|---|
| 09:32 ET | 377 | 18.39 |
| 09:34 ET | 600 | 18.28 |
| 09:36 ET | 1185 | 18.669 |
| 09:38 ET | 2468 | 18.66 |
| 09:45 ET | 200 | 18.73 |
| 09:50 ET | 100 | 18.69 |
| 09:52 ET | 636 | 18.52 |
| 09:54 ET | 3728 | 18.33 |
| 09:56 ET | 100 | 18.4425 |
| 09:59 ET | 800 | 18.18 |
| 10:01 ET | 109 | 18.455 |
| 10:03 ET | 100 | 18.28 |
| 10:08 ET | 300 | 18.29 |
| 10:12 ET | 1600 | 18.1 |
| 10:14 ET | 100 | 18.15 |
| 10:15 ET | 200 | 18.045 |
| 10:17 ET | 12142 | 18.25 |
| 10:19 ET | 200 | 18.2998 |
| 10:21 ET | 1785 | 18.32 |
| 10:30 ET | 200 | 18 |
| 10:42 ET | 185 | 18.07 |
| 10:46 ET | 100 | 18.08 |
| 10:48 ET | 126 | 18.16 |
| 10:57 ET | 100 | 18.165 |
| 11:04 ET | 175 | 18.15 |
| 11:11 ET | 100 | 18.03 |
| 11:13 ET | 100 | 18.075 |
| 11:22 ET | 200 | 17.92 |
| 11:31 ET | 500 | 18.04 |
| 11:38 ET | 100 | 18.05 |
| 11:51 ET | 200 | 17.94 |
| 12:21 ET | 200 | 17.8 |
| 12:41 ET | 25062 | 17.75 |
| 12:43 ET | 740 | 17.78 |
| 12:57 ET | 200 | 17.74 |
| 12:59 ET | 100 | 17.71 |
| 01:03 ET | 100 | 17.71 |
| 01:14 ET | 208 | 17.7426 |
| 01:15 ET | 500 | 17.74 |
| 01:19 ET | 500 | 17.91 |
| 01:30 ET | 1000 | 17.69 |
| 01:35 ET | 535 | 17.84 |
| 01:46 ET | 200 | 17.99 |
| 01:48 ET | 1400 | 18.08 |
| 01:50 ET | 100 | 18.23 |
| 01:53 ET | 100 | 18.29 |
| 01:55 ET | 500 | 18.135 |
| 01:57 ET | 100 | 18.39 |
| 02:04 ET | 100 | 18.38 |
| 02:06 ET | 3901 | 18.12 |
| 02:08 ET | 2500 | 18.04 |
| 02:20 ET | 961 | 18.1 |
| 02:22 ET | 394 | 18.08 |
| 02:42 ET | 100 | 18.125 |
| 02:47 ET | 100 | 18.115 |
| 02:49 ET | 1800 | 18.07 |
| 02:51 ET | 200 | 18.17 |
| 02:54 ET | 400 | 18.03 |
| 03:03 ET | 200 | 18.165 |
| 03:07 ET | 100 | 18.07 |
| 03:14 ET | 993 | 18.1 |
| 03:16 ET | 2418 | 18.12 |
| 03:18 ET | 3070 | 18.1 |
| 03:20 ET | 200 | 18.09 |
| 03:21 ET | 1000 | 18.08 |
| 03:23 ET | 200 | 18.23 |
| 03:25 ET | 900 | 18.13 |
| 03:27 ET | 800 | 18.14 |
| 03:32 ET | 300 | 18.17 |
| 03:34 ET | 300 | 18.29 |
| 03:38 ET | 100 | 18.33 |
| 03:39 ET | 600 | 18.23 |
| 03:41 ET | 1498 | 18.07 |
| 03:43 ET | 635 | 18.259 |
| 03:45 ET | 400 | 18.2 |
| 03:48 ET | 1000 | 18.3 |
| 03:50 ET | 100 | 18.295 |
| 03:52 ET | 300 | 18.48 |
| 03:54 ET | 100 | 18.49 |
| 03:56 ET | 300 | 18.49 |
| 03:57 ET | 500 | 18.47 |
| 03:59 ET | 1357 | 18.55 |
Jul 2, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PepGen Inc | 584.2M | -5.7x | --- |
Anavex Life Sciences Corp | 578.9M | -13.6x | --- |
Corbus Pharmaceuticals Holdings Inc | 592.6M | -8.3x | --- |
Eliem Therapeutics Inc | 594.4M | -16.2x | --- |
Oculis Holding AG | 531.8M | -6.2x | --- |
Terns Pharmaceuticals Inc | 568.5M | -7.2x | --- |
Company Information
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Contact Information
- Headquarters
- 245 Main St, 2nd FloorCAMBRIDGE, MA, United States 02142
- Phone
- 703-456-8000
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Laurie Keating
- President, Chief Executive Officer, Treasurer, Secretary, Director
- James Mcarthur
- Chief Financial Officer
- Noel Donnelly
- Senior Vice President - Investor Relations and Corporate Communications
- Dave Borah
- Senior Vice President - Portfolio and Program Management
- Afsaneh Mohebbi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $584.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 32.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.25 |
Book Value | $4.55 |
P/E Ratio | -5.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
